1.Devita VT　J,　Hellam S,　Rosenberg SA,　et al.Biologic therapy of cancer.Philadelphia:　JB Lippmcott,1995.

2.Frank A Scappaticci.The therapeutic potential of novel an genic therapies.Ex pert Opin Investig Drugs,2003,12(6):923-932.

3.Sorokin P.New agents and future directions in biotherapy.Clin JOncol Nurs,2002,6(1):19-24.

4.Nasu Y.Gene therapy for castration resistant prostate cancer.Nihon Rinsho,2014,72:2152-2157.

5.Liu SX,Xia ZS,Zhong YQ.Gene therapy in pancreatic cancer.World JGastroenterol,2014,20:13343-13368.

6.Herbst RS.Targeted therapy in non-small-cell lung cancer.Oncology,2002,16(9 Suppl 9):19-24.

7.Mehlis S,Gordon KB.From laboratory to clinic:rationale for biologic therapy.Dermatol Clin,2004,22(4):371-377.

8.Yamamoto A,Sato T.Locoregional treatment of malignant hepatic tumors with biologic response modifiers.Surg Oncol Clin N Am,2008,17:935-955.

9.Mey U,Strehl J,Gorschluter M,et al.Advances in the teatment of hairy-cell leukaemia.Lancet Oncol,2003,4(2):86-94.

10.Hehlnan NR.Current CML therapy:progress and dilemma.Leukemia,2003,17(6):1010-1012.

11.Khler KC,Egberts F,Hauschild A,et al.Adjuvant systemic treatment ofmelanoma.Hautarzt,2011,62(6):414,416-422.

12.Groenewegen G,Walraven M,Vermaat J,et al.Targeting the Endothelin Axis with Atrasentan,in combination with IFN-alpha,inmetastatic renal cell carcinoma.Br JCancer,2012,106(2):284-289.

13.Weber JS,Mule JJ.Cancer immunotherapymeets biomaterials.Nat Biotechnol,2015,33:44-45.

14.Sabbatino F,Wang Y,Wang X,et al.Novel tumor antigen-specific monoclonal antibody-based immunotherapy to eradicate both differentiated cancer cells and cancer-initiating cells in solid tumors.Semin Oncol,2014,41:685-699.

15.Tojo A.Currentstatus and future perspective in imatinib therapy against CML.Rinsho Ketsueki,2011,52:1603-1609.

16.Demaria S,Pikarsky E,Karin M,et al.Cancer and inflammation:promise for biologic therapy.J Immunother,2010,33:335-351.

17.Su PJ,Chen JS,Liaw CC,etal.Biochemotherapywith carmustine,cisplatin,dacarbazine,tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma.Chang Gung Med J,2011,34(5):478-486.

18.Okada H.Biologic therapy for brain cancers--based on cellular and immunobiology.Yonsei Med J,2004,45(30)Suppl:68-70.

19.Shibamoto Y,Jeremic B.Biologic premises of combined radiation therapy and chemotherapy in lung cancer.Hematol Oncol Clin North Am,2004,18(1):29-40.

20.Puzik A,Moller J,Meiss F,et al.Side effects of interferon therapy in adolescentmelanoma.Pediatr Hematol Oncol,2014,31:380-381.

21.Waldmann TA.The biology of IL-15:implications for cancer therapy and the treatmentof autoimmune disorders.J Investig Dermatol Symp Proc,2013,16:S28-S30.

22.Kwak LW.Translational development of active immunotherapy for hematologic malignancies.Semin Oncol,2003,30(3 Suppl 8):17-22.

23.Shahin Rafii.Vaccination against tumor neovascularization:Promise and reality.Cancer Cell,2002:429-431.

24.Sharma C,Horowitz D,Chabot J,Saif MW.Adjuvant Therapy of Pancreatic Cancer.Highlights from the"2011 ASCO Annual Meeting".Chicago,IL,USA;June 3-7,2011.JOP,2011,12:343-346.

25.Bast RC Jr,Ravdin P,Hayes DF,et al.2000 update of recommendations for the use of tumormarkers in breastand colorectal cancer:clinical practice guidelines of the American Society of Clinical Oncology.JClin Oncol,2001,19(6):1865-1878.

26.Bi F,Fan D,HuiH,etal.Reversion of themalignant phenotypes of gastric cancer by c-erbB-2 specific ribozymes.Cancer Gene Therapy,2001,8(11):835-842.

27.Slamon DJ,Leyland-Jones B,Shak S,etal.Use of chemotherapy plus amonoclonal antibody against HER2 formetastatic breast cancer that overexpresses HER2.N Eng1 JMed,2001,344(11):783-792.

28.Reff ME,Hariharan K,Braslawsky G.Future ofmonoclonal antibodies in the treatment of hematologic malignancies.Cancer Control,2002,9(2):152-166.

29.Krasner C,Joyce RM.Zevalin:90yttrium labeled anti-Cd20(ibritumormab tiuxetan),a new treatment for non-Hodgkin's lymphoma.Curr Pharm Biotechnol,2001,2(4):341-349.

30.Chahin M,Ozer H.Biologic responsemodifiers:Principle of immunotherapy//Michael C Perry.The chemotherapy Source Book.2 ^nd ed.Baltimore:Williams&Wilkins,1996.

31.Pangalis GA,Dimopoulou MN,Angelopoulou MK,et al.Campath-1H(anti-CD52)monoclomal antibody therapy in lymphoproliferative disorders.Med Oncol,2001,18(2):99-107.

32.Folkman J,Heymach JV,KalluriR.Tumor angiogenesis.//Kufe DW.CancerMedieine,7th.Hamilton,Ontario,Canada:B.C.Decker,2005(7).

33.Folkman J.Tumor angiogenesis:Therapeutic implication.N Eng JMed,1971,285:1182.

34.Hanahan D,Folkman J.Patterns and emergingmechanisms of angiogenic switch during tumorigenesis.Cell,1996(86):353.

35.黄文林.肿瘤分子靶向治疗.北京:人民卫生出版社,2009:98.

36.李勇,孙燕,张湘茹.肿瘤的抗血管生成治疗研究进展,癌症进展杂志,2008(6):1.

37.阎锡蕴.肿瘤新生血管及分子靶向治疗新策略.生物物理学报,2010,26(3):180-193.

38.Yamanaka K,Saito J,NakataW,etal.Case of drug-induced colitis like ulcerative colitis during IL-2 therapy formultiple bone metastasis after operation of kidney cancer.Nihon Hinyokika Gakkai Zasshi,2009,100:586-589.

39.Yang JC,Sherry RM,Steinberg SM,et al.Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.JClin Oncol,2003,21(16):3127-3132.

40.Sievers EL,Linenberger M.Mylotarg:antibody-targeted chemotherapy comes of age.Curr Opin Oncol,2001,13(6):522-527.